April 2019

HHPF past president David Rabago, MD, presented the abstracts of two prolotherapy studies as lectures at the elite North American Primary Care Research Group (NAPCRG) conference in Chicago, IL, in November 2018. Both won prestigious PEARL awards (; each was selected from among over 1000 peer-reviewed abstracts as those “most likely to influence clinical practice”.

The awards suggest that prolotherapy is gaining visibility in conventional (compared with alternative) medical venues. The HHPF is involved in both studies through funding (tennis elbow study) and collaboration (both studies). Principal investigators Michael Yelland (Australia) and Regina Sit (Hong Kong) have presented at the annual HHPF Prolotherapy Research Symposium; the manuscripts for both studies are in review with peer-reviewed journals.

Abstracts Presented:

Intra-Articular Hypertonic Dextrose Prolotherapy Reduces Knee Pain in Knee Osteoarthritis: A One Year Blinded Randomized Controlled Trial
David Rabago, MD; Ricky Wu; Kenneth Reeves, MD; Dicken Chan; Benjamin HK Yip; Vincent Chung; Samuel, Yeungshan Wong; Regina Sit

Prolotherapy, Physiotherapy and Combination Care for Lateral Epicondylalgia: A 3-Arm Single-Blinded Randomized Clinical Trial
Michael Yelland; David Rabago, MD; Michael Ryan; Shu-Kay Ng; Dinusha Vithanachchi; Nagarajan Manickaraj; Leanne Bisset